As of December 31, 2025, Atlas Arteria Ltd. carries a market capitalization of 4.72B, placing it among publicly traded companies globally. Its enterprise value stands at 7.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.72B |
| Enterprise Value | 7.50B |
Atlas Arteria Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.
| Earnings Date | 2/24/2027 |
As of December 31, 2025, Atlas Arteria Ltd. has 1.45B shares outstanding.
| Shares Outstanding | 1.45B |
As of December 31, 2025, Atlas Arteria Ltd. trades at a trailing price-to-earnings ratio of 27.26. The price-to-sales ratio is 44.52, and the price-to-book ratio stands at 2.28.
| PE Ratio | 27.26 |
| PS Ratio | 44.52 |
| PB Ratio | 2.28 |
| P/TBV Ratio | 6.57 |
As of December 31, 2025, Atlas Arteria Ltd. trades at an EV/EBITDA multiple of 231.65 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 70.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.50B versus a market cap of 4.72B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 70.71 |
| EV / EBITDA | 231.65 |
As of December 31, 2025, Atlas Arteria Ltd. maintains a current ratio of 2.17, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.96, indicating elevated leverage, while an interest coverage ratio of 0.50 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.17 |
| Quick Ratio | 2.15 |
| Debt / Equity | 29.96 |
| Debt / EBITDA | 35.84 |
| Interest Coverage | 0.50 |
Over the twelve months ended December 31, 2025, Atlas Arteria Ltd. posted a return on equity (ROE) of 8.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.29, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 3.26, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.49, useful for judging operating efficiency across full business cycles.
| Return on Equity (ROE) | 8.05 |
| Return on Assets (ROA) | 3.26 |
| Return on Invested Capital (ROIC) | -0.29 |
| Return on Capital Employed (ROCE) | 5.49 |
Over the twelve months ended December 31, 2025, Atlas Arteria Ltd. recorded 5.34M in income tax expense. That works out to an effective tax rate of 4.21, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 126.69M, leaving 173.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 5.34M |
| Effective Tax Rate | 4.21 |
As of the close on November 3, 2026, Atlas Arteria Ltd.'s stock has declined approximately 15.69% over the past 52 weeks. The 50-day moving average sits at 3.35, while the 200-day moving average is 3.44.
| 52-Week Price Change | -15.69% |
| 50-Day Moving Average | 3.35 |
| 200-Day Moving Average | 3.44 |
Over the twelve months ended December 31, 2025, Atlas Arteria Ltd. generated 106.07M in revenue and converted that into 173.22M in net income, yielding earnings per share of 0.08. EBITDA reached 32.37M, while operating income came in at -15.62M.
| Revenue | 106.07M |
| Gross Profit | 91.25M |
| Operating Income | -15.62M |
| Pretax Income | 126.69M |
| Net Income | 173.22M |
| EBITDA | 32.37M |
| EBIT | -15.62M |
| Earnings Per Share (EPS) | 0.08 |
As of December 31, 2025, Atlas Arteria Ltd. holds 183.17M in cash and equivalents against 1.16B in total debt, resulting in a net debt position of 959.15M. Total book value stands at 2.07B, with working capital of 103.93M providing operational flexibility.
| Cash & Cash Equivalents | 183.17M |
| Total Debt | 1.16B |
| Net Debt | 959.15M |
| Equity (Book Value) | 2.07B |
| Book Value Per Share | 1.43 |
| Working Capital | 103.93M |
These figures cover the twelve months ended December 31, 2025.
| Capital Expenditures | -400,507.31 |
Over the twelve months ended December 31, 2025, Atlas Arteria Ltd. posted a gross margin of 86.03, reflecting its pricing power and cost economics. The operating margin of -14.73 and net profit margin of 163.31 provide insight into operational efficiency.
| Gross Margin | 86.03 |
| Operating Margin | -14.73 |
| Pretax Margin | 119.45 |
| Profit Margin | 163.31 |
| EBITDA Margin | 30.52 |
Over the twelve months ended December 31, 2025, Atlas Arteria Ltd. paid dividends of 0.27 per share. The dividend payout ratio of 557.54 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 9.76, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Atlas Arteria Ltd. shareholders.
| Dividend Per Share | 0.27 |
| Payout Ratio | 557.54 |
| Shareholder Yield | 9.76 |
Atlas Arteria Ltd.'s most recent stock split took place on September 16, 2022 with a 100:107 split ratio.
| Last Split Date | 9/16/2022 |
| Split Ratio | 100:107 |
As of December 31, 2025, Atlas Arteria Ltd. has an Altman Z-Score of 2.04, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.04 |
Already premium?